Antithrombotic therapy with Transcatheter aortic valve replacement

Research output: Contribution to journalReview articlepeer-review


Aortic valve replacement is a necessary management strategy for patients with severe aortic stenosis. The use of transaortic valve replacement (TAVR) has increased significantly over the last decade and now exceeds traditional surgical aortic valve replacement. Since the valve systems used in TAVR consist of bioprosthetic valve tissue encased in a metal stent frame, antithrombotic therapy recommendations cannot be extrapolated from prior data with differently constructed surgical bioprosthetic or mechanical valves. Data on the use of antithrombotic therapy with TAVR are a rapidly developing area of medicine. Choice of agents depends on several patient factors. Patients undergoing TAVR also have a relatively high incidence of subclinical valve thrombosis. The clinical impact of this phenomenon and the implications for antithrombotic therapy continue to evolve. It is critical for clinicians who treat patients undergoing TAVR to have a firm understanding of practice guidelines, the evolving evidence, and its implications for the use of antithrombotic therapy in these patients.

Original languageEnglish (US)
Pages (from-to)1064-1083
Number of pages20
Issue number10
StatePublished - Oct 2023


  • anticoagulant
  • antiplatelet
  • antithrombotic
  • thrombosis
  • transcatheter aortic valve

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Antithrombotic therapy with Transcatheter aortic valve replacement'. Together they form a unique fingerprint.

Cite this